Search Medical Condition
Please enter condition
Please choose location

Tyumen, Russian Federation Clinical Trials

A listing of Tyumen, Russian Federation clinical trials actively recruiting patients volunteers.

RESULTS

Found (12) clinical trials

Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS

This is an event driven study to reach statistical power given all other assumptions. Subjects will visit the clinic 1 month after randomization and at regular intervals thereafter. Additionally, for any subject prematurely discontinuing study medication, assessments will be conducted every 6 months for the collection of study endpoints. Those ...

Phase

0.0 miles

Learn More »

International Multicenter Observational Non-Interventional Prospective Study of Azilsartan Medoxomil in Participants With Arterial Hypertension Who Are Overweight or Obese in the Russian Federation and The Republic of Kazakhstan

The drug being tested in this study is called azilsartan medoxomil. Azilsartan medoxomil is being tested to treat people who have hypertension. This study will look at the clinic systolic and diastolic blood pressure (SBP, DBP) in obese participants who will be prescribed with azilsartan medoxomil by physician. The study ...

Phase N/A

1.03 miles

Learn More »

Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis

This is a randomized, double-blind, double-dummy, active comparator-controlled, parallel-group, multi-center study with variable treatment duration in approximately 900 patients with relapsing MS. The maximal treatment duration in the study for an individual patient will be 2.5 years. Eligible patients will be randomized to receive either experimental ofatumumab subcutaneous (sc) injections ...

Phase

2.3 miles

Learn More »

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.

This is a multi-center, open label, phase IV study to provide continued supply of pasireotide to patients being treated in a current Novartis-sponsored, Oncology CD&MA study and who are benefiting from treatment with pasireotide. Eligible patients are to be consented and can then continue treatment with pasireotide in this protocol. ...

Phase

2.59 miles

Learn More »